Deep Analysis of Acquired Resistance to FGFR1 Inhibitor Identifies MET and AKT Activation and an Expansion of AKT1 Mutant Cells

Oncotarget - United States
doi 10.18632/oncotarget.25862
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib

Scientific Reports
Multidisciplinary
2018English

Transcriptome Profiling of Cervical Cancer Cells Acquired Resistance to Cisplatin by Deep Sequencing

Artificial Cells, Nanomedicine and Biotechnology
MedicineBiotechnologyBiomedical EngineeringPharmaceutical Science
2019English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy
OncologyPharmacology
2015English

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

Cancer Research
Cancer ResearchOncology
2011English

Activation of the Met Kinase Confers Acquired Drug Resistance in FGFR-targeted Lung Cancer Therapy

Oncogenesis
Cancer ResearchMolecular Biology
2016English

Combating Acquired TRK Inhibitor Resistance

Cancer Discovery
Oncology
2019English

Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas

Oncotarget
Oncology
2016English

Overexpression of HMGA1 Promotes Anoikis Resistance and Constitutive Akt Activation in Pancreatic Adenocarcinoma Cells

British Journal of Cancer
Cancer ResearchOncology
2007English

X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells With Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy